Grifols, S.A. (NASDAQ:GRFS) Receives $10.30 Consensus PT from Analysts

Key Points

• Grifols, S.A. has received a consensus rating of "Moderate Buy" from five research firms, with three hold recommendations, one buy, and one strong buy.
• The company's stock price target has been raised to $10.30 by analysts, following updates from firms such as JPMorgan and Wall Street Zen.
• Grifols is set to pay a dividend of $0.1404 per share on August 20th, with a dividend payout ratio of 11.97%.

Shares of Grifols, S.A. (NASDAQ:GRFS - Get Free Report) have earned a consensus rating of "Moderate Buy" from the five ratings firms that are presently covering the company, MarketBeat reports. Three research analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $10.30.

A number of research firms recently commented on GRFS. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Grifols in a report on Tuesday, August 5th. Wall Street Zen raised Grifols from a "buy" rating to a "strong-buy" rating in a report on Monday, July 7th. JPMorgan Chase & Co. boosted their price target on Grifols from $7.60 to $10.30 and gave the company a "neutral" rating in a report on Tuesday, June 17th. Finally, Zacks Research raised Grifols to a "hold" rating in a report on Friday, August 8th.

Institutional Investors Weigh In On Grifols

Hedge funds have recently bought and sold shares of the stock. Versant Capital Management Inc purchased a new position in shares of Grifols in the 1st quarter valued at about $28,000. Tower Research Capital LLC TRC increased its holdings in shares of Grifols by 354.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,124 shares of the biotechnology company's stock valued at $60,000 after acquiring an additional 6,335 shares during the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of Grifols by 127.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 8,219 shares of the biotechnology company's stock valued at $74,000 after acquiring an additional 4,604 shares during the last quarter. First Trust Advisors LP purchased a new position in shares of Grifols in the 4th quarter valued at about $75,000. Finally, Ballentine Partners LLC purchased a new position in shares of Grifols in the 1st quarter valued at about $77,000.

Grifols Stock Performance

Shares of Grifols stock traded up $0.0470 on Friday, reaching $10.2370. 386,083 shares of the stock were exchanged, compared to its average volume of 984,851. The company has a quick ratio of 0.95, a current ratio of 2.64 and a debt-to-equity ratio of 1.20. Grifols has a twelve month low of $6.19 and a twelve month high of $11.14. The firm has a market capitalization of $7.04 billion, a price-to-earnings ratio of 8.74, a PEG ratio of 0.36 and a beta of 0.56. The business has a 50 day moving average price of $9.71 and a two-hundred day moving average price of $8.31.

Grifols Announces Dividend

The firm also recently declared a -- dividend, which will be paid on Wednesday, August 20th. Stockholders of record on Tuesday, August 12th will be issued a dividend of $0.1404 per share. The ex-dividend date is Tuesday, August 12th. Grifols's dividend payout ratio is currently 11.97%.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.